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Summary
Moment-to-moment adjustment of cerebral blood flow (CBF) via neurovascular cou-
pling has an essential role in maintenance of healthy cognitive function. In advanced
age, increased oxidative stress and cerebromicrovascular endothelial dysfunction
impair neurovascular coupling, likely contributing to age-related decline of higher
cortical functions. There is increasing evidence showing that mitochondrial oxidative
stress plays a critical role in a range of age-related cellular impairments, but its role
in neurovascular uncoupling remains unexplored. This study was designed to test
the hypothesis that attenuation of mitochondrial oxidative stress may exert benefi-
cial effects on neurovascular coupling responses in aging. To test this hypothesis,
24-month-old C57BL/6 mice were treated with a cell-permeable, mitochondria-tar-
geted antioxidant peptide (SS-31; 10 mg kg1 day1, i.p.) or vehicle for 2 weeks.
Neurovascular coupling was assessed by measuring CBF responses (laser speckle
contrast imaging) evoked by contralateral whisker stimulation. We found that neu-
rovascular coupling responses were significantly impaired in aged mice. Treatment
with SS–31 significantly improved neurovascular coupling responses by increasing
NO-mediated cerebromicrovascular dilation, which was associated with significantly
improved spatial working memory, motor skill learning, and gait coordination. These
findings are paralleled by the protective effects of SS–31 on mitochondrial produc-
tion of reactive oxygen species and mitochondrial respiration in cultured cerebromi-
crovascular endothelial cells derived from aged animals. Thus, mitochondrial
oxidative stress contributes to age-related cerebromicrovascular dysfunction, exacer-
bating cognitive decline. We propose that mitochondria-targeted antioxidants may
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be considered for pharmacological microvascular protection for the prevention/
treatment of age-related vascular cognitive impairment (VCI).
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1 | INTRODUCTION
Normal functioning of the central nervous system (CNS) requires a
continuous, tightly controlled supply of oxygen and nutrients as
well as washout of harmful metabolites through uninterrupted
cerebral blood flow (CBF). The energetic demands of neurons are
very high, yet the brain has very little energetic reserves. During
periods of intense neuronal activity, there is a requirement for
adjusting oxygen and glucose delivery to local neuronal activity
through rapid adaptive increases in CBF. This is ensured by a
mechanism known as neurovascular coupling (NVC). The resultant
functional hyperemia is a vital mechanism to maintain optimal
microenvironment of cerebral tissue and thereby ensuring normal
neuronal function.
There is an increasing appreciation that (micro)vascular contribu-
tions to cognitive impairment and dementia in elderly patients are
critical (Tarantini, Tran, Gordon, Ungvari & Csiszar, 2016). Impor-
tantly, neurovascular coupling responses are impaired both in elderly
patients (Fabiani et al., 2013; Stefanova et al., 2013; Topcuoglu,
Aydin & Saka, 2009; Zaletel, Strucl, Pretnar-Oblak & Zvan, 2005)
and aged laboratory animals (Park, Anrather, Girouard, Zhou & Iade-
cola, 2007; Toth et al., 2014), which likely contributes significantly
to the progressive age-related decline in higher cortical function,
including cognition (Sorond, Hurwitz, Salat, Greve & Fisher, 2013)
and gait coordination (Sorond et al., 2011). Experimental studies sup-
port this concept, showing that pharmacologically induced neurovas-
cular uncoupling in mice mimics important aspects of age-related
cognitive impairment (Tarantini et al., 2015). On the basis of these
findings, we proposed that novel therapeutic interventions should be
developed to rescue functional hyperemia in elderly patients to pre-
vent/delay cognitive impairment (Toth et al., 2014).
There is strong evidence that microvascular endothelial NO syn-
thesis/release is stimulated during increased neuronal activity (via
ATP-mediated activation of endothelial purinergic receptors), which
critically contribute to functional hyperemia under normal conditions
(Toth, Tarantini, Davila et al., 2015). Previous studies demonstrate
that aging exacerbates generation of reactive oxygen species (ROS)
in the cerebromicrovascular endothelial cells, which contribute to
age-related neurovascular uncoupling in aged mice by promoting
endothelial dysfunction (Toth et al., 2014). We hypothesize that
pharmacological treatments, which attenuate endothelial oxidative
stress and rescue NO mediation, will have the capacity to improve
neurovascular coupling in aged individuals.
The mitochondrial free radical theory of aging posits that mito-
chondria-derived ROS (mtROS) production and related mitochon-
drial dysfunction are a critical driving force in the aging process. In
support of this theory, it was demonstrated that attenuation of
mitochondrial oxidative stress (by mitochondria-targeted overex-
pression of catalase) increases mouse lifespan (Schriner & Linford,
2006). Further, pharmacological treatments that attenuate mtROS
production were shown to counteract some of the effects of aging
in skeletal muscle (Siegel et al., 2013) and the heart (Dai, Chiao,
Marcinek, Szeto & Rabinovitch, 2014; Dai, Rabinovitch & Ungvari,
2012; Dai et al., 2011). There is particularly strong evidence that
mitochondrial oxidative stress is implicated in cardiovascular aging
processes (Dai et al., 2012; Springo et al., 2015). Yet, although
drugs that improve mitochondrial function have been shown to
exert beneficial effects both on the vasomotor function of periph-
eral arteries (Gioscia-Ryan et al., 2014; Pearson et al., 2008), their
potential protective effects on the aged cerebral microvasculature
has not been investigated.
This study was designed to test the hypothesis that pharmaco-
logical attenuation of mtROS can restore cerebromicrovascular
endothelial function and thus improve neurovascular coupling in
aged mice. To achieve this goal, in aged mice mitochondrial oxidative
stress was manipulated by treatment with the mitochondrial-targeted
Szeto-Schiller (SS) peptide SS–31. SS–31 is a tetrapeptide with alter-
nating aromatic-cationic amino acid motif (H-D-Arg-Dmt-Lys-Phe-
NH2), which concentrates in the inner mitochondrial membrane more
than 1,000-fold compared with the cytosolic concentration (Bakeeva
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et al., 2008; Doughan & Dikalov, 2007; Zhao et al., 2004) and is able
to effectively reduce levels of O2
, H2O2, hydroxyl radical and per-
oxynitrite both in vitro and in vivo (Graham et al., 2009; Szeto,
2008; Zhao et al., 2004). Mice were behaviorally evaluated on a bat-
tery of tests for characterization of cognitive function and motor
coordination and functional tests for neurovascular coupling
responses and cerebromicrovascular endothelial function. Markers of
oxidative stress and expression of genes regulating neurovascular
coupling responses in the cerebral cortex were assessed. To substan-
tiate the in vivo findings, the effects of SS–31 on mitochondrial ROS
production and mitochondrial respiration in cerebromicrovascular
endothelial cells derived from aged animals were obtained in vitro.
2 | RESULTS
2.1 | Treatment with SS-31 rescues neurovascular
coupling responses in aged mice by restoring NO
mediation
CBF responses in the whisker barrel cortex elicited by contralateral
whisker stimulation were significantly decreased in aged mice com-
pared to young animals indicating impaired neurovascular coupling in
aging (representative laser speckle contrast images and CBF tracings
are shown in Figure 1a,c; summary data are shown in Figure 1b,d)
(Park et al., 2007). We found that a 14-day treatment with SS–31
significantly increased CBF responses induced by contralateral whis-
ker stimulation in aged mice, restoring neurovascular coupling to
levels observed in young mice (Figure 1).
Studies using an open cranial window preparation showed that
in young animals administration of the NO synthase inhibitor L-
NAME significantly decreased neurovascular coupling responses,
eliminating the differences between the age groups (representative
laser Doppler tracings are shown in Figure 2a; summary data are
shown in Figure 2b). In untreated aged animals, administration of L-
NAME was without effect (Figure 2a,b). In contrast, in SS–31-treated
aged mice L-NAME significantly decreased CBF responses elicited
by whisker stimulation (Figure 2a,b), suggesting that SS–31 treat-
ment restored the NO mediation of neurovascular coupling in aged
animals.
2.2 | Treatment with SS-31 improves endothelial
function in aged cerebral vessels
To further ascertain the endothelial protective effects of SS-31,
endothelium-dependent vasodilator responses were tested in iso-
lated, cannulated branches of the MCA. Pressurized MCAs devel-
oped spontaneous myogenic tone (~30%), the magnitude of which
did not differ between the experimental groups. In young vessels,
administration of acetylcholine (Figure 2c) and ATP (Figure 2d)
resulted in significant dilation, whereas these responses were signifi-
cantly attenuated in vessels derived from aging mice (Figure 2c,d).
Treatment of aged mice with SS-31 significantly improved both
acetylcholine- and ATP-induced vasodilation, restoring responses to
the level observed in vessels of young mice. To assess the role of
endothelium-derived NO, L-NAME was applied. L-NAME signifi-
cantly inhibited acetylcholine- and ATP-induced dilator responses,
eliminating the differences between the three groups. These finding
suggests that SS-31 significantly improves endothelial function by
restoring endothelial NO mediation in aged cerebral vessels.
Vasodilator responses elicited by administration of the NO donor
sodium nitroprusside (SNP) did not differ significantly among the
experimental groups (Figure 2e), suggesting that the dilator capacity
of smooth muscle cells in the aged cerebral vasculature is preserved
and is unaffected by SS-31.
2.3 | SS-31 attenuates mitochondrial oxidative
stress and improves mitochondrial respiration in aged
cerebromicrovascular endothelial cells
To substantiate the endothelial protective effects of SS-31 in vitro,
we assessed the effects of SS-31 on cellular mtROS production in
cultured CMVECs derived from aged animals using the MitoSox fluo-
rescence method. We found that mtROS production in CMVECs
derived from aged animals was significantly increased as compared
to that in CMVECs derived from young animals (Figure 2f). SS-31
treatment elicited significant decreases in mtROS production in aged
CMVECs, eliminating the difference between the two age groups
(Figure 2f). The antioxidative effects of SS-31 were manifested
rapidly, with maximal reduction in mtROS being evident after 2 hr
post-treatment (Figure 2f). Attenuation of mtROS production in aged
CMVECs was associated with significant improvement in mitochon-
drial respiration (Figure 2 g), which is compatible with the idea that
SS-31 energizes mitochondria, promoting electron transport and
optimizing mitochondrial ATP synthesis at the same time as it
reduces ROS generation by escape of free electrons from the respi-
ratory chain (Birk, Chao, Bracken, Warren & Szeto, 2014; Birk et al.,
2013).
2.4 | Effects of treatment with SS-31 on expression
of genes regulating NO mediation in the aged mouse
brain
Treatment with SS-31 did not alter the expression of Nos1 and Nos3
in the aged mouse brain (Figure 2h). The expression of arginase 1
was increased in aged mice and tended to be downregulated by SS-
31 treatment. NADPH oxidases are also important sources of ROS
in the cerebral vasculature, whose increased expression and activity
may contribute to impaired neurovascular coupling (Park et al.,
2007; Toth et al., 2014). We found that in the cortex of aged mice
mRNA expression of the NADPH-oxidase subunits Nox1 and Nox2
were upregulated compared to young mice (Figure 2i), extending
recent findings (Park et al., 2007; Toth et al., 2014). Expression of
Nox2 in SS-31-treated aged CMVECs was statistically not different
from that in young CMVECs (Figure 2h). Treatment with SS-31 did
not alter the expression of Nox1, Sod1 and Sod2 in the aged mouse
brain (Figure 2h).
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2.5 | Restoration of cerebromicrovascular function
is associated with improved cognitive function in
aged mice treated with SS-31
Previous studies show that selective pharmacologically induced neu-
rovascular uncoupling is associated with cognitive impairment
(Tarantini et al., 2015). To determine how restoration of cerebromi-
crovascular function impacts cognitive function in aged mice, animals
were tested in the radial-arm water maze (Figure 3a). We compared
the learning performance of mice in each experimental group by ana-
lyzing the day-to-day changes in the combined error rate, successful
escape rate, degree of divergence, path length, and time latency.
During acquisition, mice from all groups showed a decrease in the
combined error rate (Figure 3b) across days, indicating learning of
the task. After the first day of learning, young mice consistently had
lower combined error rate than aged mice (Figure 3b). Treatment
with SS-31 did not alter the combined error rate in aged mice.
To analyze working memory function (short-term memory that is
involved in immediate conscious perception), we examined re-entries
into incorrect arms (without hidden platform) that were previously
attempted for escape. We found that working memory function was
impaired in aged mice as compared to young controls (Figure 3c).
Aged mice that were treated with SS-31 showed significant
restoration of working memory to levels comparable to young ani-
mals (Figure 3c). SS-31 treatment thus resulted in a marked improve-
ment in working memory while there was no clear effect of SS-31
on learning.
Successful escape rate from the maze was assessed by measur-
ing the percent of animals that could find the hidden platform within
the 60 s allowed for each trial. During acquisition, mice from all
groups showed an increase in successful escape rate consistent with
the learning of the task. Young mice exhibited significantly better
escape success than untreated aged mice (Figure 3d). SS-31 treat-
ment significantly increased the successful escape rate in aged mice,
restoring it to the level observed in young mice (Figure 3d). We
attribute, at least in part, the higher successful escape rate in young
maze-na€ıve mice and SS-31-treated aged maze-na€ıve mice to the
more effective search strategy they used as indicated by the lower
degree of divergence.
We also compared path length (i.e., the distance that the mouse
swam between maze entry and successful escape through the hid-
den platform) and escape latency (i.e., the time elapsed between
entry and successful escape). During acquisition, mice from all
groups displayed shorter path length (Figure 3e) and lower escape
latencies (Figure 3f), indicating spatial learning. Young mice exhibited
significantly shorter path length (Figure 3e) and lower escape latency
F IGURE 1 Treatment with SS-31 rescues neurovascular coupling in aged mice. Panel a–b: Representative pseudocolor laser speckle
flowmetry maps of baseline CBF (Panel a) and CBF changes in the whisker barrel field relative to baseline during contralateral whisker
stimulation (Panel b, right oval, 30 s, 5 Hz) in young (3 months old), aged (24 months old), and SS-31-treated aged mice. Color bar represents
CBF as percent change from baseline. Panel c shows the time course of CBF changes after the start of contralateral whisker stimulation
(horizontal bars). Summary data are shown in panel d. Data are mean  SEM. (n = 6–8 in each group), *p < .05 vs. young; #p < .05 vs. aged.
(one-way ANOVA with post hoc Tukey’s tests)
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F IGURE 2 Treatment with SS-31 improves microvascular endothelial function and rescues NO mediation of neurovascular coupling response
in aged mice. Panel a: Representative traces of cerebral blood flow (CBF; measured with a laser Doppler probe above the whisker barrel cortex)
during contralateral whisker stimulation (30 s, 5 Hz) in the absence and presence of the NO synthase inhibitor L-NAME in young (3 months old),
aged (24 months old), and SS-31-treated aged mice. Summary data are shown in panel b. *p < .05 vs. young; #p < .05 vs. aged. (one-way ANOVA
with post hoc Tukey’s tests) Panel c–d: Dilation of cannulated branches of the middle cerebral artery, isolated from young, aged, and SS-31-treated
aged mice, in response to the endothelium-dependent vasodilator acetylcholine (c) and ATP (d) in the absence and presence of the NO synthase
inhibitor L-NAME (3 9 104 M). Panel e: Vascular dilations to the endothelium-independent aged.; n.s.: not significant. Panel f: Time course for
changes in mtROS production in aged CMVECs induced by treatment with SS-31 (105 M). Data are mean  SEM. (n = 8 in each group). *p < .05
vs. young control; #p < .05 vs. aged control. Panel g: Attenuation of mtROS production in aged CMVECs was associated with significant
improvement in cellular oxygen consumption rate (OCR; a marker of oxidative phosphorylation; see Methods). Data are mean  SEM. (n = 8 in
each group). *p < .05 vs. young control; #p < .05 vs. aged control. Panel h: qPCR data showing cortical mRNA expression of nitric oxide synthases
Nos3 and Nos1, arginases (Arg1, Arg2), NADPH oxidases (Nox1, Nox2), and superoxide dismutases (Sod1, Sod2) in young, aged, and SS-31-treated
aged mice. Data are mean  SEM. (n = 6–7 in each group). *p < .05 vs. young control; #p < .05 vs. aged control
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F IGURE 3 In SS-31-treated aged mice, rescue of neurovascular coupling responses associates with improved radial-arm water maze
(RAWM) performance. Young (3 months old), aged (24 months old), and SS-31-treated aged mice were tested in the RAWM. Panel a: Heatmap
representing the percentage of time spent in different locations in the maze for a randomly selected animal from each group during
experimental day 3. Note that the untreated aged mouse required a greater amount of time and a longer path length in order to find the
hidden escape platform. Older mice also re-enter a previously visited arm multiple time, accruing working memory errors. Panel b: Older
animals have higher combined error rates throughout days 2 and 3 of the learning phase and retrieval day 10 (p < .0001). Combined error rate
is calculated by adding 1 error for each incorrect arm entry as well as for every 15 s spent not exploring the arms. Panel c: Older animals
make significantly more working memory errors (repetitive incorrect arm entries) as compared to young mice. In contrast, aged mice treated
with SS-31 perform this task significantly better than untreated aged mice (p = .04). Panel d: The ratio of successful escapes, averaged across
trial blocks, is shown for each group. Note day-to-day improvement in the performance of young mice, which was significantly delayed in aged
mice. Aged mice treated with SS-31 were more successful at finding the hidden escape platform in comparison with untreated age-matched
controls (p < .0001). Panel e: Average path length required to reach the hidden platform in the RAWM for trial blocks 1–6 and for probe trial
on day 10. Young mice find the hidden platform while swimming significantly less than aged animals (p < .0001). In aged mice treated with SS-
31, the average path length required to reach the hidden platform did not differ from that in young mice. Panel f: Escape latencies to find the
hidden platform in the RAWM for aged control mice are significantly higher when compared to young and aged treated mice (p < .0001 for
both comparisons). Panel g: There was no significant difference in swimming speed among all experimental groups. Panel h: SS-31 treatment
reduced the time spent engaged in nonexploratory behavior in control-treated old mice as compared to young animals. (p < .0001). n = 20 in
each group. All data are shown as mean  SEM. Statistical significance was calculated using one-way ANOVA with Tukey’s post hoc test to
determine differences among groups
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(Figure 3f) than untreated aged mice, which differences remained
pronounced on day 3 of acquisition and the probe trial. In contrast,
in aged mice treated with SS-31 path length and escape latencies
were similar to that observed in young mice (Figure 3e,f). The analy-
ses of noncognitive parameters revealed no difference in swimming
speed and only a slight, age-dependent increase in nonexploratory
behavior (the cumulative time the mice spent not actively looking
for the platform, e.g., floating), which was reduced in SS-31-treated
animals (Figure 3g,h). Taken together, the aforementioned results
suggest that in aged mice SS-31 treatment improved performance in
the radial-arm water maze, which results from enhanced hippocam-
pal-dependent spatial learning and memory and not from changes in
motor or motivational processes.
2.6 | Treatment with SS-31 restores motor learning
function in aged mice
To investigate the effects of age and SS-31 treatment on the motor
performance of mice, we measured grip strength and inverted grid
hang time (data not shown), which evaluates muscle strength and
endurance. We found that neither aging nor SS-31 treatment
affected the outcome of these tests.
Motor skill learning was assessed using a modified rotarod test.
During a 4-day-long experimental period, young mice displayed a
steeper motor skill learning curve compared to aged control mice.
After the first day, aged control animals consistently fell off the
accelerating rotarod earlier compared to young controls, showing
impaired acquisition of motor skill learning. Treatment with SS-31
restored motor skill learning behavior to the young control levels
(Figure 4a).
2.7 | Treatment with SS-31 does not restore gait
function in aged mice
Age-related deficiencies in neurovascular coupling responses in
human patients have been linked to gait abnormalities (Sorond et al.,
2011). To identify subtle age- and treatment-related differences
between mouse gait patterns, principal component analysis (PCA)
was carried out on the correlation matrix of averages of spatial and
temporal indices of gait. This analysis identified three principal com-
ponents that accounted for ~68% of the variance in the data. We
plotted the position of each mouse against the PC1, PC2, and PC3
axes in three-dimensional space (Figure 4b). The most conspicuous
trend was that young and aged mice appeared well separated along
F IGURE 4 SS-31 treatment in aged mice improves motor skill
learning but not gait coordination. a) Motor skill learning on the
accelerating rotarod. Daily changes in mean latencies to fall for
young (3 months old), aged (24 months old) and SS-31-treated aged
mice are shown. Data are mean  SEM. (n = 20 in each group).
*p < .05 vs. young control; #p < .05 vs. aged control. b) 3D triplot of
first three principal components (PC) identified by PCA on the
correlation matrix of spatial and temporal indices of gait. Each point
represents an individual mouse, and centroids are shown for each
experimental group. Note that mice in the same age groups
clustered together. Distance between centroids is shown inset.
Whole differences between young and aged mouse gait were
evident, rescue of NVC responses by SS-31 treatment did not
reverse age-related changes in mouse gait (MANOVA; p = .47 aged
vs. aged treated; p < .001 young vs. aged; p < .0001 young vs. aged
treated). c) Scheme showing proposed role for increased
mitochondrial oxidative stress in cerebromicrovascular endothelial
impairment and neurovascular dysfunction in aging
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the PC2 and PC3 axes. In contrast, aged mice and SS-31-treated
aged mice were clustered together.
3 | DISCUSSION
The key finding of his study is that the mitochondria-targeted
antioxidative peptide SS-31 exerts significant beneficial effects on
neurovascular coupling responses and cognitive function in a
mouse model of aging that recapitulates cerebromicrovascular
dysfunction and deficits of higher brain function manifested in
elderly patients.
Extending previous findings in elderly patients and aged labora-
tory animals, we demonstrate that aging leads to significant neu-
rovascular dysregulation in mice, characterized by diminished CBF
changes in response to increased neuronal activity (Figure 1). Here,
we demonstrate for the first time that aging-induced decline in neu-
rovascular coupling is restored by treatment with SS-31 (Figure 1).
There is strong experimental evidence that endothelial NO produc-
tion contributes importantly to neurovascular coupling (Toth et al.,
2014). This concept is supported by our observation that both
genetic depletion of eNOS (Toth, Tarantini, Davila et al., 2015) and
pharmacological inhibition of NO synthesis (Figure 2a,b) dramatically
reduce neurovascular coupling in young mice. The findings that in
aged mice inhibition of endothelial NO synthesis does not attenuate
functional hyperemia (Toth et al., 2014) (Figure 2a) suggest that
cerebromicrovascular endothelial dysfunction significantly con-
tributes to age-related neurovascular uncoupling (Figure 2b)(Park
et al., 2007). Importantly, treatment with SS-31 rescues NO media-
tion of neurovascular coupling in aged animals (Figure 2a) supporting
the concept that potent endothelial protective effects of SS-31 play
a key role in its anti-aging action. Additional evidence in support of
this concept comes from the observations that SS-31 treatment res-
cued acetylcholine- and ATP-induced, endothelial NO-mediated
vasodilation in aged mice (Figure 2c,d). It should be noted that
endothelium-derived NO also modulates cellular metabolism and
mitochondrial function, is an important inhibitor of platelet aggrega-
tion, smooth muscle cell proliferation and leukocyte adhesion, and
exerts potent anti-inflammatory, anti-apoptotic, and pro-angiogenic
effects. Therefore, SS-31 mediated improvement in microvascular
NO production likely has clinical significance beyond rescue of NVC
response, potentially exerting multifaceted protective effects on neu-
ronal, astrocytic and microglial functions.
Previous studies demonstrate that the mechanism(s) by which
aging impairs cerebromicrovascular endothelial function involves an
increased breakdown of NO by elevated levels of ROS (Toth et al.,
2014). On the basis of the findings that SS-31 treatment effectively
attenuates oxidative stress in aged CMVECs (Figure 2f–g), we pro-
pose that in aged mice SS-31 treatment restores NVC responses
and endothelium-dependent cerebromicrovascular dilation by pre-
venting oxidative stress-mediated scavenging of NO in the
microvascular endothelial cells. Recovery of endothelial function in
aged peripheral arteries has also been reported using the structurally
different mitochondria-targeted antioxidant MitoQ (Gioscia-Ryan
et al., 2014).
The mechanisms by which SS-31 attenuates mtROS production
in aging are likely multifaceted. Age-related loss of efficiency in
mitochondrial electron transport likely increases electron leak and
mtROS production. SS-31 is known to concentrate in the inner mito-
chondrial membrane more than 1,000-fold compared with the
cytosolic concentration (Bakeeva et al., 2008; Doughan & Dikalov,
2007; Zhao et al., 2004). While SS-31 may scavenge ROS directly at
the site of their production, recent studies show that SS-31 binds to
cardiolipin via electrostatic and hydrophobic interactions and thereby
protects the structure of mitochondrial cristae, increasing the effi-
ciency of mitochondrial electron transport (Siegel et al., 2013) and
attenuating mtROS production (Szeto, 2014). Increased efficiency of
ATP generation and reduction in ROS are thereby coupled. Based on
the findings that SS-31 improves mitochondrial respiration in cere-
bromicrovascular endothelial cells (Figure 2h), while reducing ROS
generation (Figure 2f,g) we posit that such a mechanism is opera-
tional in the cerebral microcirculation of SS-31-treated aged mice.
There are studies suggesting that upregulation of the tissue renin–
angiotensin II system (Wang et al., 2007) contributes to increased
vascular oxidative stress in aging (Modrick, Didion, Sigmund & Faraci,
2009). Importantly, SS-31 was also shown to effectively attenuate
angiotensin II-induced mtROS production (Dai et al., 2011). The
microvascular endothelium in the brain, which maintains the blood–
brain barrier and exhibits controlled transcellular transport systems,
has high energy demands. Future studies should determine how SS-
31-induced changes in cellular energetics impact barrier and trans-
port function in aged CMVECs. In addition, there is growing evi-
dence that mitochondria-derived ROS regulate the expression and
activity of plasma membrane-associated NADPH oxidases in vascular
cells (reviewed in Dai et al. (2012)). Accordingly, in the cerebral cir-
culation of aged mice increased mitochondrial oxidative stress is
associated with an upregulated expression and activity of NADPH
oxidases (Park et al., 2007; Toth et al., 2014), which appear to be
partially reversed by SS-31 (Figure 2i) as well as by other interven-
tions that attenuate mtROS production in aging (Toth et al., 2014).
Interestingly, SS-31-induced downregulation of NADPH oxidases has
also been observed previously in the heart (Dai et al., 2011) and the
kidney (Hou et al., 2016). Thus, we posit that SS-31 may also alter
the interplay between mitochondria and NADPH oxidases, disrupting
a vicious feed-forward cycle that diminishes NO bioavailability and
promotes neurovascular uncoupling. Furthermore, one can hypothe-
size that SS-31 treatment of aged mice may also attenuate astro-
cyte-derived ROS generation, in addition to its beneficial endothelial
effects, thereby improving astrocyte-mediated neurovascular cou-
pling responses (e.g., by decreasing production of constrictor arachi-
donic acid metabolites). This possibility should be tested in future
studies.
There is a growing appreciation of vascular contributions to cog-
nitive decline and dementia. Importantly, clinical studies suggest that
impairment of NVC responses contributes to the age-related decline
in higher cortical functions (Sorond et al., 2011, 2013). Recent
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studies demonstrate that BOLD signal is positively correlated with
working memory in rodent models and that impaired memory is
associated with impaired NVC (reduced BOLD activity) in the hip-
pocampus (Febo & Foster, 2016). Our recent studies provide strong
experimental evidence in support of this concept, demonstrating that
impairment of NVC responses and cognitive decline in mice are cau-
sally related (Tarantini et al., 2015). The present study is the first to
demonstrate that restoration of NVC by SS-31 treatment in aging is
associated with improvement in multiple domains of brain function,
including hippocampal-dependent memory functions (Figure 3). Pre-
viously, we found that restoration of NVC responses in aged mice
by treatment with resveratrol (Toth et al., 2014) is also associated
with marked improvement in cognitive function (Oomen et al.,
2009). It is significant that resveratrol is a potent inhibitor of mtROS
production in endothelial cells (Ungvari et al., 2009). Human studies
show that procedural motor learning is affected by NVC responses
(Grafton, Woods & Tyszka, 1994) and becomes significantly impaired
during aging. It is thus significant that SS-31 treatment rescues
motor skill learning in aged mice (Figure 4). Age-related deficiencies
in NVC responses in human patients have been also linked to gait
abnormalities (Sorond et al., 2011). Recent studies also show that in
a mouse model of radiation-induced accelerated brain aging (Ungvari
et al., 2017) impaired NVC also predicts gait abnormalities. The pre-
sent study identified systematic differences between young and
aged mouse gait using PCA. However, rescue of NVC responses by
SS-31 treatment did not reverse age-related changes in mouse gait
(Figure 4c).
Our findings have important clinical relevance. In humans, SS-
31 (elamipretide) is well tolerated with no reports of significant
side effects (Szeto, 2014) and its potential to exert renoprotective
and cardioprotective effects is currently being evaluated in clinical
trials (Szeto, 2014). Thus, future clinical trials with SS-31 in elderly
patients are feasible, which would allow its potential in improving
cerebromicrovascular and cognitive outcomes to be evaluated.
Importantly, NVC is also compromised both in patients with Alzhei-
mer’s disease (AD) and in animal models of AD, which is believed
to trigger and/or exacerbate cognitive decline (Tarantini et al.,
2016). Further, the mitochondria-targeted antioxidant MitoQ was
shown to prevent cognitive decline in mouse models of AD
(McManus, Murphy & Franklin, 2011). Thus, our results are also
likely relevant to the development of novel treatments of AD as
well. Importantly, SS-31 and related tetrapetides can cross the
blood–brain barrier; thus, long-term treatment has the added
advantage that it may inhibit inflammatory processes associated
with AD as well.
In conclusion, our results demonstrate that SS-31 treatment
exerts cerebromicrovascular protective effects in aged mice. SS-31
treatment improved endothelial function and rescued neurovascular
coupling responses in the aged cortex, which likely contributes to
improvements of higher cortical function. Our findings point to
the potential use of mitochondria-targeted antioxidants as therapy
for prevention of vascular cognitive impairment associated with
aging.
4 | EXPERIMENTAL PROCEDURES
Materials, experimental procedures, and statistical analyses are
described in detail in the Data S1.
4.1 | Animals, SS-31 treatment
Young (3 months, n = 30) and aged (24 months, n = 40) male
C57BL/6 mice were used. Mice in the aged cohort were assigned to
two groups (n = 20 each group). One group of the aged mice was
injected daily with SS-31 (elamipretide; also known as MTP-131 or
Bendavia, 10 mg Kg1day1, for 10 days). This dosage of SS-31 has
been shown to exert potent cardioprotective effects (Dai et al.,
2011). All procedures were approved by the Institutional Animal Use
and Care Committees of the University of Oklahoma Health
Sciences Center.
4.2 | Behavioral studies
After the treatment period, behavioral tasks were performed to char-
acterize the effect of SS-31 treatment on learning and memory, sen-
sory-motor function, gait and locomotion (n = 20 in each group).
4.3 | Radial-arm water maze testing
Spatial memory and long-term memory in each group of mice was
tested using the radial-arm water maze as described (Ungvari et al.,
2017).
4.4 | Rotarod, motor skill learning
Motor coordination was assessed using the rotarod as described
(Tarantini et al., 2015). Analysis of day-to-day changes in perfor-
mance on the accelerating rotarod test was used to evaluate the
motor skill learning. The grid hanging test was also used to evaluate
balance and motor function. A grip strength test was used to mea-
sure the maximal muscle strength of forelimbs of the mice.
4.5 | Analysis of gait function
To determine how aging and SS-31 treatment affect gait coordina-
tion, we tested the animals using an automated computer-assisted
method (CatWalk; Noldus Information Technology Inc. Leesburg, VA,
USA) as described (Tarantini et al., 2015; Toth, Tarantini, Springo
et al., 2015).
4.6 | Measurement of neurovascular coupling
responses
After behavioral testing, mice in each group were anesthetized with
isoflurane (4% induction and 1% maintenance), endotracheally intu-
bated, and ventilated. Neurovascular coupling responses were
assessed by measuring changes in cerebral blood flow above the left
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barrel cortex using laser speckle contrast imaging in response to
contralateral whisker stimulation (Toth et al., 2014; Toth, Tarantini,
Ashpole et al., 2015; Toth, Tarantini, Davila et al., 2015). In a sepa-
rate cohort of mice, the role of NO mediation in NVC responses
was tested. In brief, in anesthetized, intubated and ventilated mice
equipped with an open cranial window, changes in CBF were
assessed above the left barrel cortex using a laser Doppler probe
in response to electric stimulation of the contralateral whisker pad,
as described (Tarantini et al., 2015; Toth et al., 2014; Toth, Taran-
tini, Ashpole et al., 2015). Changes in CBF were averaged and
expressed as percent (%) increase from the baseline value. To
assess the role of NO mediation, CBF responses to whisker stimu-
lation were repeated in the presence of the nitric oxide synthase
inhibitor Nx-Nitro-L-arginine methyl ester (L-NAME; 3 9 104 M,
20 min).
4.7 | Assessment of endothelial NO-mediated
vasodilation in isolated cerebral vessels
To assess the specific effect of SS-31 treatment on endothelial NO
mediation, isolated segments of the middle cerebral arteries were
cannulated and pressurized, as reported (Springo et al., 2015; Toth
et al., 2013). Dilations to acetylcholine (108–105 M) and ATP
(107 M) (administered in the bath) were obtained in the absence
and presence of L-NAME (3 9 104 M, for 30 min). To assess
endothelium-independent vasodilation, responses to the NO donor
sodium nitroprusside (SNP, 107 M) were assessed. At the end of
each experiment, the vessels were superfused with Ca2+-free Krebs’
buffer containing nifedipine (105 M) to achieve maximal
vasodilatation.
4.8 | Quantitative real-time RT–PCR
A quantitative real-time RT–PCR technique was used to analyze
mRNA expression in cortical samples using validated TaqMan probes
(Applied Biosystems) and a Strategen MX3000 platform, as previ-
ously reported (Toth, Tarantini, Ashpole et al., 2015).
4.9 | Assessment of the effect of in vitro treatment
with SS-31 on age-related increases in mtROS
production in cultured cerebromicrovascular
endothelial cells
To confirm the direct antioxidative endothelium-protective effect
of SS-31 in vitro, we assessed the effect of SS-31 (109–105 M,
for 24 hr or 105 M, for 1–24 hr) on mtROS production in cul-
tured primary cerebromicrovascular endothelial cells (CMVECs)
derived from young and aged rats. The establishment and charac-
terization of the cell strains used have been recently reported
(Csiszar et al., 2014). Mitochondrial O2
 production in CMVECs
was measured by flow cytometry using MitoSox Red (3 lM for
30 min), a mitochondrion-specific hydroethidine-derivative fluores-
cent dye, as reported.
4.10 | Seahorse respirometry
To substantiate the endothelium-protective effect of SS-31, we per-
formed real-time measurements of the oxygen consumption rate
(OCR; a marker of oxidative phosphorylation) in young and aged
CMVECs after treatment with SS-31 (105 M, for 48 hr) using a
Seahorse XF96 extracellular flux analyzer.
4.11 | Statistical analysis
Data were analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s post hoc test. Principal component analysis, fol-
lowed by MANOVA and the PCA-biplot approach were used to
analyze the gait data. A p value less than .05 was considered statisti-
cally significant. Data are expressed as mean  SEM.
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